Pfizer CFO Dave Denton to Step Down, Cecile Guegan Named Interim Finance Chief

Written By :  sheeba farhat
Published On 2026-06-21 05:00 GMT   |   Update On 2026-06-21 05:00 GMT
Pfizer
Advertisement

Bengaluru: ​Pfizer said on Thursday ​that finance chief Dave Denton will leave on August 15 ​to return to the consumer goods industry, after helping the U.S. drugmaker navigate its post-COVID transition.

The company named Cecile Guegan, senior vice president of finance for its global ‌biopharmaceuticals business, ⁠as ⁠interim chief financial officer. Guegan has held a range of finance roles over 20 years ​at Pfizer.

Shares of the company were down 1.6% at $25.4 in premarket trading.

Scotiabank analyst ​Louise Chen said Denton's exit raises concerns among investors about the company's 2026 forecast, succession plans and the timing of the move when Pfizer ​is preparing to enter the obesity drug ⁠market.

A FOUR-YEAR RUN

Denton, ‌who succeeded long-time Pfizer finance chief Frank D'Amelio ​in 2022, ​joined from home-improvement chain Lowe's Cos and was previously ⁠CFO at CVS Health, where he worked for nearly 20 ​years.

His tenure at Pfizer coincided with an aggressive ​dealmaking phase as the company used the windfall from its COVID-19 vaccine and antiviral treatment to buy cancer-focused Seagen, migraine drugmaker Biohaven and weight-loss treatment developer Metsera.

The deals aimed to soften the hit from declining sales of its COVID vaccine and antiviral treatment and prepare ‌for looming patent expirations on key products.

CEO Albert Bourla has set a goal of adding $20 billion in revenue by ​2030, but expects ​to return to ⁠growth after 2028.

The company's shares have nearly halved since Denton took over as CFO, as investors worried whether the acquisitions and internal drug development ​programs can offset the revenue shortfall.

Despite the lingering concerns, shares have gained about 4% so far this year. Pfizer said it will conduct an internal and external search for a permanent successor.Denton and Guegan will work together on the transition, the company said.

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News